

Reporting Guidelines for Health Care Simulation Research:
Extensions to the CONSORT and STROBE Statements

Cheng A¹, Kessler D², Mackinnon R³, Chang T⁴, Nadkarni V⁵, Hunt EA⁶, Duval-Arnould J⁶, Lin Y⁷, Cook
DA⁸, Pusic M⁹, Hui J¹⁰, Moher D¹¹, Egger M¹², Auerbach M¹³ for the International Network for
Simulation-based Pediatric Innovation, Research and Education (INSPIRE) Reporting Guidelines
Investigators*

Corresponding Author:

¹Adam Cheng, MD, FRCPC
Associate Professor, University of Calgary
KidSim-ASPIRE Research Program, Division of Emergency Medicine
Department of Pediatrics, Alberta Children's Hospital
2888 Shaganappi Trail NW
Calgary, Alberta, Canada T3B 6A8

Email: cheng@me.com
Phone : 403 955 2633
Fax : 403 955 7552 (attention – Keely Piscopo)

Authors:

²David Kessler, MD, MSc
Columbia University College of Physicians and Surgeons
Email: dk2592@cumc.columbia.edu

³Ralph Mackinnon, BSc, MBChB, FRCA
Royal Manchester Children's Hospital
Central Manchester University Hospitals NHS Foundation Trust
Email: ralph.mackinnon@cmft.nhs.uk

⁴Todd P Chang, MD, MAcM
Children's Hospital Los Angeles, University of Southern California
Email: dr.toddchang@gmail.com

⁵Vinay M. Nadkarni MD
The Children's Hospital of Philadelphia,
University of Pennsylvania Perelman School of Medicine
Email: nadkarni@email.chop.edu

⁶Elizabeth A. Hunt, MD, MPH, PhD, Jordan Duval-Arnould, MPH, CPH, DrPH[c]
Johns Hopkins University School of Medicine
Email: ehunt@jhmi.edu; jordan@jhu.edu

⁷Yiqun Lin MD, MHSc
Alberta Children's Hospital,
Cumming School of Medicine, University of Calgary
Email: jeffylin@hotmail.com

⁸David A. Cook, MD, MHPE
Multidisciplinary Simulation Center, Mayo Clinic Online Learning, and Division of General Internal
Medicine
Mayo Clinic College of Medicine
Email: cook.david33@mayo.edu

⁹Martin Pusic MD, PhD
Institute for Innovations in Medical Education, Division of Education Quality & Analytics,
NYU School of Medicine
Email: martin.pusic@nyumc.org

¹⁰Joshua Hui, MD, MSc
Department of Emergency Medicine,
David Geffen School of Medicine at UCLA
Email: joshhui@gmail.com

¹¹David Moher, PhD
Ottawa Methods Centre, Clinical Epidemiology Program,
Ottawa Hospital Research Institute
Email: dmoher@ohri.ca

¹²Matthias Egger MD, MSc
Institute of Social and Preventive Medicine
University of Bern
matthias.egger@ispm.unibe.ch

¹³Marc Auerbach, MD, MSc
Department of Pediatrics, Section of Emergency Medicine,
Yale University School of Medicine
Email: dr.auerbach@gmail.com

*INSPIRE Network Reporting Guideline Working Group: Dylan Bould, MBChB, MRCP, FRCA, Med,
University of Ottawa, dylanbould@gmail.com; Ryan Brydges, PhD, University of Toronto,
r.brydges@gmail.com; Michael Devita, MD, FCCM, FACP, Harlem Hospital Center,
mdevita06@gmail.com; Jonathan Duff, MD, MEd, University of Alberta,
jon.duff@albertahealthservices.ca; Sandeep Gangadharan, MD, Hofstra University School of Medicine,
gangadsa@gmail.com; Sharon Griswold-Theodorson, MD, MPH, Drexel University College of Medicine,
Sharon.griswold-theodorson@drexelmed.edu; Pam Jeffries, PhD, RN, FAAN, ANEF, George Washington
University, pjeffries@gwu.edu; Lindsay Johnston, MD, Yale University School of Medicine,
Johnston.lindsayc@gmail.com; Suzan Kardong-Edgren, PhD, RN, ANEF, CHSE, Robert Morris
University, kardongedgren@rmu.edu; Arielle Levy, MD, MEd, University of Montreal,
arielle.levy007@gmail.com; Lori Lioce, DNP, FNP-BC, CHSE, FAANP, The University of Alabama in
Huntsville, lioceb@uah.edu; Marco Luchetti, MD, MSc, A. Manzoni General Hospital,
m.luchetti@fastwebnet.it; Tensing Maa, MD, Ohio State University College of Medicine,
tensing.maa@nationwidechildrens.org; William McGaghie, PhD, Northwestern University Feinberg
School of Medicine, wmcgaghie@luc.edu; Taylor Sawyer, DO, MEd, University of Washington School of
Medicine, tlsawyer@uw.edu; Dimitrios Stefanidis, MD, PhD, FACS, Carolinas HealthCare System,
dimitrios.stefanidis@carolinashelathcare.org; Kathleen Ventre, MD, Children's Hospital Colorado,
Kathleen.ventre@ucdenver.edu; Barbara Walsh, MD, University of Massachusetts School of Medicine,
bwalshmd1@gmail.com; Mark Adler, MD, Feinberg School of Medicine, Northwestern University, m-adler@northwestern.edu; Linda Brown, MD, MSCE, Alpert Medical School of Brown University,
lbrown8@lifespan.org; Aaron Calhoun, MD, University of Louisville, aaron.calhoun@louisville.edu;
Aaron Donoghue, MD, MSCE, The Children's Hospital of Philadelphia, Donoghue@email.chop.edu; Tim
Draycott, MD, FRCOG, Southmead Hospital, tdraycott@me.com; Walter Eppich, MD, MEd, Feinberg
School of Medicine, Northwestern University, weppich@gmail.com; Marcie Gawel, MSN, BSN, MS, Yale
University, Marcie.gawel@yale.edu; Stefan Gisin, MD, University Hospital Basel, Stefan.gisin@usb.ch;
Lou Halamek, MD, Stanford University, halamek@stanford.edu; Rose Hatala, MD, MSc, University of
British Columbia, rhatala@mac.com; Kim Leighton, PhD, RN, ANEF, DeVry Medical International's
Institute for Research and Clinical Strategy, [kleighton@devrygroup.com](mailto:kleichton@devrygroup.com); Debra Nestel, PhD, Monash
University, debra.nestel@monash.edu; Mary Patterson, MD, MEd, Cincinnati Children's Hospital,
marydpatterson84@gmail.com; Jennifer Reid, MD, University of Washington School of Medicine,

Jennifer.reid@seattlechildrens.org; Elizabeth Sinz, MD, FCCM, Penn State University College of
 Medicine, esinz@psu.edu; G. Ulufer Sivrikaya, MD, Antalya Training and Research Hospital,
ulufers@gmail.com; Kimberly Stone, MD, MS, MA, University of Washington School of Medicine,
Kimberly.stone@seattlechildrens.org; Anne Marie Monachino, MSN, RN, CPN, Children's Hospital of
 Philadelphia, monachino@email.chop.edu; Michaela Kolbe, PhD, University Hospital Zurich,
mkolbe@ethz.ch; Vincent Grant, MD, FRCPC, University of Calgary,
Vincent.grant@albertahealthservices.ca; Jack Boulet, PhD, Foundation for Advancement of International
 Medical Education and Research, jboulet@faimer.org; David Gaba, MD, Stanford University School of
 Medicine, gaba@stanford.edu; Peter Dieckmann, PhD, Dipl-Psych, Danish Institute for Medical
 Simulation, mail@peter-dieckmann.de; Jeffrey Groom, PhD, CRNA, Florida International University,
groomj@flu.edu; Chris Kennedy, MD, University of Missouri Kansas City School of Medicine,
ckennedy@cmh.edu; Ralf Krage, MD, DEAA, VU University Medical Center, r.krage@vumc.nl; Leah
 Mallory, MD, The Barbara Bush Children's Hospital at Maine Medical Center, mallol@mmc.org; Akira
 Nishisaki, MD, MSCE, The Children's Hospital of Philadelphia, nishisaki@email.chop.edu; Denis Oriot,
 MD, PhD, University Hospital of Poitiers, denis.oriot@gmail.com; Christine Park, MD, Feinberg School of
 Medicine, Northwestern University, csparkmd@gmail.com; Marcus Rall, MD, InPASS Institute for Patient
 Safety and Teamtraining, marcus.rall@inpass.de; Nick Sevdalis, PhD, King's College London,
n.sevdalis@kcl.ac.uk; Nancy Tofil, MD, MEd, University of Alabama at Birmingham,
ntofil@peds.uab.edu; Debra Weiner, MD, PhD, Boston Children's Hospital,
debra.weiner@childrens.harvard.edu; John Zhong, MD, University of Texas Southwestern Medical Center,
john.zhong@childrens.com; Donna Moro-Sutherland, MD, Baylor College of Medicine,
donnamsutherland@gmail.com; Dalit Eyal, DO, St. Christopher's Hospital for Children,
dalit.eyal@drexelmed.edu; Sujatha Thyagarajan, DCH, FRCPC, PediSTARS India, sujadoc@gmail.com;
 Barbara Ferdman, MD, University of Rochester Medical Center, brferdman@gmail.com; Grace Arteaga,
 MD, FAAP, Mayo Clinic (Rochester), arteaga.grace@mayo.edu; Tonya Thompson, MD, MA, The
 University of Arkansas for Medical Sciences, thompstonyam@uams.edu; Kim Rutherford, MD, St.
 Christopher's Hospital for Children, kim.rutherford@drexelmed.edu; Frank Overly, MD, Alpert Medical
 School of Brown University, foverly@lifespan.org; Jim Gerard, MD, Saint Louis University School of
 Medicine, gerardjm@slu.edu; Takanari Ikeyama, MD, Aichi Children's Helath and Medical Center,
taqnary@gmail.com; Angela Wratney, MD, MHSc, Children's National Medical Center,
awratney@cnmc.org; Travis Whitfill, MPH, Yale University School of Medicine, travis.whitfill@yale.edu;
 Nnenna Chime, MD, MPH, Albert Einstein College of Medicine, nnenna_chime@yahoo.com; John Rice,
 PhD(c), US Department of the Navy (retired), john.rice@noboxes.org; Tobias Everett, MBChB, FRCA,
 The Hospital for Sick Children, tobias.everett@sickkids.ca; Wendy Van Ittersum, MD, Akron Children's
 Hospital, wenvan@gmail.com; Daniel Scherzer, MD, Nationwide Children's Hospital,
Daniel.scherzer@nationwidechildrens.org; Elsa Vazquez Melendez, MD, FAAP, FACP, University of
 Illinois College of Medicine at Peoria, eluciav@uic.edu; Chris Kennedy, MD, University of Missouri
 Kansas School of Medicine, ckennedy@cmh.edu; Waseem Ostwani, MD, University of Michigan Health
 System, waseem@med.umich.edu; Zia Bismilla, MD, MEd, The Hospital for Sick Children,
zia.bismilla@sickkids.ca; Pavan Zaveri, MD, MEd, Children's National Health System,
pzaveri@childrensnational.org; Anthony Scalzo, MD, FACMT, FAAP, FAACT, Saint Louis University
 School of Medicine, scalzoaj@slu.edu; Daniel Lemke, MD, Baylor College of Medicine,
dslemke@texaschildrens.org; Cara Doughty, MD, MEd, Baylor College of Medicine,
cbdought@texaschildrens.org; Modupe Awonuga, MD, MPH, MRCP(UK), FRCPC, FAAP, Michigan
 State University, awonuga@msu.edu; Karambir Singh, MD, Johns Hopkins University School of Medicine,
ksingh14@jhu.edu; Melinda Fiedor-Hamilton, MD, MSc, Children's Hospital of Pittsburgh,
fiedml@ccm.upmc.edu

Manuscript Word Count: 3129 words

Abstract Word Count: 250 words

Abstract

Introduction: Simulation-based research is rapidly expanding but the quality of reporting needs improvement. For a reader to critically assess a study, the elements of the study need to be clearly reported. Our objective was to develop reporting guidelines for simulation-based research by creating extensions to the CONSORT (Consolidated Standards of Reporting Trials) and STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) Statements.

Methods: An iterative multi-step consensus-building process was used based on the recommended steps for developing reporting guidelines. The consensus process involved: (1) Developing a steering committee; (2) Defining the scope of the reporting guidelines; (3) Identifying a consensus panel; (4) Generating a list of items for discussion via online pre-meeting survey; (5) Conducting a consensus meeting; and (6) Drafting reporting guidelines with an explanation and elaboration document.

Results: Eleven extensions were recommended for CONSORT: item 1 (title/abstract), item 2 (background), item 5 (interventions), item 6 (outcomes), item 11 (blinding), item 12 (statistical methods), item 15 (baseline data), item 17 (outcomes/estimation), item 20 (limitations), item 21 (generalizability), and item 25 (funding). Ten extensions were drafted for STROBE: item 1 (title/abstract), item 2 (background/rationale), item 7 (variables), item 8 (data sources/measurement), item 12 (statistical methods), item 14 (descriptive data), item 16 (main results), item 19 (limitations), item 21 (generalizability), and item 22 (funding). An elaboration document was created to provide examples and explanation for each extension.

Conclusions: We have developed extensions for the CONSORT and STROBE Statements that can help to improve the quality of reporting for simulation-based research.

Introduction

Simulation has seen growing use in health care as a “tool, device and/or environment (that mimics an aspect of clinical care”¹ in order to improve health care provider performance, health care processes, and ultimately, patient outcomes¹⁻⁵. The use of simulation in health care has been accompanied by an expanding body of simulation-based research (SBR) addressing both educational and clinical issues⁶⁻¹⁵. Broadly speaking, SBR can be broken down into two categories: (1) research addressing the efficacy of simulation as a training methodology (ie. simulation-based education as the subject of research); and (2) research using simulation as an investigative methodology (ie. simulation as the environment for research)^{16,17}. Many features of SBR overlap with traditional clinical or educational research. However, the use of simulation in research introduces a unique set of features that must be considered when designing the methodology, and reported when publishing the study¹⁶⁻¹⁹.

As has been shown in other fields of medicine²⁰, the quality of reporting in health professions education research is inconsistent and sometimes poor^{1,11,21-23}. Systematic reviews in medical education have quantitatively documented missing elements in the abstracts and main texts of published reports, with particular deficits in the reporting of study design, definitions of independent and dependent variables, and study limitations²¹⁻²³. In research specific to simulation for health care professions education, a systematic review noted many studies failing to “clearly describe the context, instructional design or outcomes”¹. Another study found that only 3% of studies incorporating debriefing in simulation education reported all the essential characteristics of debriefing¹¹. Failure to adequately describe the key elements of a research study impairs the efforts of editors, reviewers, and readers to critically appraise strengths and weaknesses^{24,25} or apply and replicate findings²⁶. As such, incomplete reporting represents a limiting factor in the advancement of the field of simulation in health care.

Recognition of this problem in clinical research has led to the development of a growing number of reporting guidelines in medicine and other fields, including the Consolidated Standards of Reporting Trials (CONSORT) Statement for randomized trials²⁷⁻³⁰, the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement for observational studies^{31,32}, and the Preferred Reporting Items for Systematic Review and Meta-Analyses (PRISMA) Statement³³⁻³⁵, amongst more than 250 others³⁶. Transparent reporting of research allows readers to clearly identify and understand “what was

planned, what was done, what was found, and what conclusions were drawn”³¹. In addition to these statements, experts have encouraged³⁷ and published extensions to existing statements that focus on specific methodological approaches^{38,39} or clinical fields^{40,41}. In this study, we aimed to develop reporting guidelines for SBR by creating extensions to the CONSORT Statement and the STROBE Statement specific to the use of simulation in health care research. These reporting guidelines are meant to be used by authors submitting manuscripts involving SBR, and to assist editors and journal reviewers when assessing the suitability of simulation-based studies for publication.

Methods

The study protocol was reviewed by the Yale University Biomedical Institutional Review Board and was granted exempt status. We conducted a multi-step consensus process based on previously described steps for developing health research reporting guidelines⁴². These steps involved: (1) Developing a steering committee; (2) Defining the scope of the reporting guidelines; (3) Identifying a consensus panel; (4) Generating a list of items for discussion; (5) Conducting a consensus meeting; and (6) Drafting reporting guidelines and an explanation and elaboration document.

Development of the Steering Committee

A steering committee was formed consisting of 12 members with expertise in simulation-based education and research, medical education research, study design, statistics, epidemiology, and clinical medicine. The steering committee defined the scope of the reporting guidelines, identified participants for the consensus process, generated a pre-meeting survey, planned and conducted the consensus meeting and ultimately, drafted and refined the final version of the reporting guidelines and the explanation and elaboration document.

Defining the Scope of the Reporting Guidelines

To clarify the scope of the reporting guideline extensions, we defined simulation as encompassing a diverse range of products including computer-based virtual reality simulators, high fidelity and static mannequins, plastic models and task trainers, live animals, inert animal products, human cadavers, and

standardized or simulated patients (ie. individuals trained to portray a patient). Our definition excluded research using computational simulation and mathematical modeling, as the guidelines were developed for research using human participants, either as learners or health care providers¹. The steering committee determined to create reporting guidelines encompassing two categories of SBR: (1) studies evaluating simulation for educational use; and (2) studies using simulation as investigative methodology¹⁶. We identified the CONSORT²⁸ and STROBE^{31,32} statements as reflecting the current reporting standards in health care research and aimed to develop extensions of these two statements for quantitative simulation-based research. The CONSORT Statement and extensions were developed for randomized trials, and the STROBE Statement and extensions were developed for observational studies (cohort, case-control, and cross-sectional study designs). Our guideline extensions are not intended for qualitative research, mixed-methods research or for validation studies.

Identification of Consensus Panel Participants

The steering committee aimed to identify a consensus group with a broad range of expertise in SBR, including experience in conducting single and multicenter simulation-based studies, expertise in educational research, statistics, clinical epidemiology, and research methodology, and with varying clinical backgrounds. We invited the Editor-in-Chief and editorial board members of three health care simulation journals: *Simulation in Healthcare*, *BMJ Simulation and Technology-Enhanced Learning*, and *Clinical Simulation in Nursing*, and editorial board members from two medical education journals: *Medical Education* and *Advances in Health Sciences Education*. In total, 60 expert participants were invited to complete the online survey.

Generating a List of Items for Discussion

Prior to the consensus meeting, we surveyed the expert participants via a pre-meeting survey (www.surveymonkey.com) to identify items in the CONSORT and STROBE Statements that required an extension for SBR. The survey included all items from both the CONSORT and STROBE Statements, and was pilot tested amongst steering committee members before being posted online. Participants were asked to provide suggested wording for the items they identified as requiring an extension. Participants were also

given the option of suggesting new simulation-specific items for both the CONSORT and STROBE Statements. Based on methods previously used to develop extensions to the CONSORT Statement⁴⁰, we used a cutoff of endorsement by at least 1/3 of respondents to identify high priority items for discussion during the consensus meeting.

Consensus Meeting

A five-hour consensus conference was conducted January 2015 in New Orleans, USA during the annual International Network for Simulation-based Pediatric Innovation, Research and Education (INSPIRE) meeting. The initial 60 consensus panel participants were invited to attend the consensus conference as well as INSPIRE network members (i.e. clinicians, researchers, educators, psychologists, statisticians and epidemiologists). The INSPIRE network is the world's largest health care simulation research network with a proven track record of conducting rigorous simulation-based studies in health care⁴³⁻⁵⁰.

The results of the online survey were circulated to each member of the steering committee, who was then assigned to review specific items from the CONSORT and STROBE statements based on their expertise. The consensus meeting started with a brief didactic presentation reviewing the CONSORT and STROBE Statements, followed by a description of the study objectives and consensus process. In small groups, each steering committee member led a discussion with 4 or 5 individuals tasked with determining if a simulation-specific extension was required for their assigned items, and if so, to recommend wording for the extension. Consensus panel participants were evenly distributed amongst small groups and specifically assigned to review items based on their area of expertise. High priority items were discussed at length, but all other checklist items were also discussed in the small groups.

Following small group discussion, the recommended simulation-specific extensions for both the CONSORT and STROBE Statements were presented to the entire group of participants. Each proposed extension was discussed before recommended wording was established. Minutes from the small and large group discussions were used to inform the development of the explanation and elaboration document⁴².

Drafting Reporting Guidelines

The proposed extensions were circulated for comment amongst all meeting participants and consensus panel participants who could not attend the meeting. The steering committee used the comments to further refine the extension items. To evaluate these items in practice, four members of the steering committee independently pilot tested both the CONSORT and STROBE statements with simulation-specific extensions. They used two published SBR studies (i.e. one for each type of SBR), while ensuring one study was a randomized trial and the other an observational study. Feedback from pilot testing informed further revisions. The final reporting guidelines with extensions were circulated to the steering committee one last time to ensure the final product accurately represented discussion during and after the consensus conference. An explanation and elaboration document was developed by the steering committee to provide further detail for each item requiring a simulation-specific extension⁴².

Results

Pre-meeting Survey

There was a 75% response rate for the survey, with 45 of the 60 participants completing the entire survey. An additional 12 (20%) other participants partially completed the survey. Of the 57 participants who responded to the survey, 17 were medical journal editors or editorial board members, 24 had advanced degrees (Masters, PhD), 16 with advanced degrees in medical education or educational psychology, six were nurses, one was a psychologist, and 54 were physicians (representing anesthesiology, critical care, emergency medicine, pediatrics, and surgery). Of the 3 participants who did not complete the survey, two were physicians and one was a scientist. The results of the survey are described in Supplemental Digital Content (See Table, Supplementary Digital Content 1, Survey Responses).

Consensus Meeting

In total, 35 consensus panel participants who completed the pre-meeting survey attended the consensus conference. An additional 30 attendees were INSPIRE network members. Of the 65 total attendees at the consensus conference, 12 were medical journal editors or editorial board members, 18 had advanced degrees (Masters, PhD), four were nurses, one was a psychologist, and 60 were physicians (representing anesthesiology, critical care, emergency medicine, pediatrics, and surgery).

Eleven simulation-specific extensions were recommended for the CONSORT Statement: item 1 (title and abstract), item 2 (background), item 5 (interventions), item 6 (outcomes), item 11 (blinding), item 12 (statistical methods), item 15 (baseline data), item 17 (outcomes and estimation), item 20 (limitations), item 21 (generalizability), and item 25 (funding). Participants agreed upon the importance of describing the rationale for and design of the simulation-based intervention. As many simulation-based studies use assessment tools as an outcome measure, participants thought it was important to report the unit of analysis and evidence supporting the validity and reliability of the assessment tool(s) when available. In the discussion section, participants thought it was important to describe the limitations of simulation-based research, and the generalizability of the simulation-based outcomes to clinical outcomes (when applicable). Participants also agreed it was important to identify the simulator brand used in the study and if conflict of interest for intellectual property existed amongst investigators. The group did not feel that modifications to the CONSORT flow diagram were required for simulation-based research. See Table 1 for CONSORT extensions for SBR.

Ten extensions were drafted for the STROBE Statement: item 1 (title and abstract), item 2 (background/rationale), item 7 (variables), item 8 (data sources/measurement), item 12 (statistical methods), item 14 (descriptive data), item 16 (main results), item 19 (limitations), item 21 (generalizability), and item 22 (funding). A similar emphasis was placed on the importance of describing all simulation-specific exposures, confounders and effect modifiers, as was discussed for the CONSORT. Other extensions for the STROBE were under similar categories as the proposed extensions for the CONSORT. See Table 2 for STROBE extensions for SBR.

For both the CONSORT and STROBE Statements, extensive discussion occurred in the consensus meeting related to the educational intervention and controlling for simulation-specific variables that pose as potential threats to the internal validity of simulation studies. A group of consensus panel participants with expertise in simulation-based education and instructional design utilized their knowledge of educational theory, existing educational research guidelines⁵¹ and systematic reviews of simulation-based research^{1,5-8,11} to address this issue (Table 3). Table 3 offers an additional checklist of key elements specific to SBR, for item 5 (Interventions) on the CONSORT Statement and item 7 (Variables) on the STROBE Statement, that should be reported for all simulation studies, for both the intervention and control groups (if applicable).

In modeling the explanation and elaboration document after other similar documents published in conjunction with reporting guidelines^{28,32}, we provide a specific example for each item requiring a new extension coupled with the background and rationale for including that information for that item. We encourage readers to refer to the explanation and elaboration document to seek further detail about the nature and type of recommended reporting for each new extension (see text, Supplemental Digital Content 2, Explanation and Elaboration of the Simulation-Specific Extensions for the CONSORT and STROBE Statements).

Discussion

We have developed reporting guidelines for SBR by creating extensions to both the CONSORT²⁸ and STROBE³¹ Statements. These new extensions were developed via a consensus building process with multiple iterative steps involving an international group of experts with diverse backgrounds and expertise. By creating extensions to both the CONSORT and STROBE Statements that can be applied to studies in both categories of SBR, we have developed reporting guidelines that are applicable to the majority of studies involving simulation in health care research. To further assist authors in reporting SBR studies, we have published an explanation and elaboration document as an appendix that provides specific examples and details for all the new simulation-specific extensions for both the CONSORT and STROBE Statements.

The CONSORT and STROBE Statements with accompanying SBR extensions are meant to serve as a guide to reporting. As with other CONSORT and STROBE Statements, the items are not meant to “prescribe the reporting.... in a rigid format”, but rather the “order and format for presenting information depends on author preferences, journal style, and the traditions of the research field”^{28,31}. We encourage authors to refer to the explanation and elaboration document that provides details regarding specific elements related to individual items that should be reported for SBR. The use of reporting guidelines can have positive effects on various health care simulation stakeholders, including funders of SBR and those applying for funding (ie. use as a template for grant applications), educators (ie. use as a training tool), and students (ie. use to develop protocols for coursework or research)³³. The application of these reporting guidelines will help to enhance quality of reporting for quantitative SBR and assist journal reviewers and

editors when faced with assessing the strengths and weaknesses of simulation-based studies in health care^{24,52,53}. We encourage journals publishing SBR to consider endorsing the simulation-specific extensions for the CONSORT and STROBE Statements and adding these to their 'Instructions for Authors'.

SBR has several unique factors that prompted us to develop simulation-specific extensions for both the CONSORT and STROBE Statements. First, there are a wide variety of simulators and simulation modalities available for use in research¹⁶. This, coupled with a plethora of instructional design features in simulation-based educational research make describing the simulation intervention a critically important component of any educational study involving simulation (Table 3)^{6,8,54}. Second, SBR provides opportunity for the investigator to standardize the simulated environment and/or simulated patient condition. Standardization of the environment and patient condition allows the investigator to account for many of the potential threats to internal validity that are associated with simulation. Clear reporting of standardization strategies helps the reader understand how the independent variable was isolated (Table 3)¹⁶. Third, many simulation studies involve capturing outcomes from a variety of data sources (eg. observation, video-review, simulator data capture). When assessment instruments are used (eg. expert raters assessing performance) it is imperative to discuss the psychometric properties of these instruments⁵. Existing guidelines fall short in this regard, and these new guidelines help to address this issue. Lastly, simulation-based studies assessing outcomes in the simulated environment only (eg. clinical performance) should attempt to provide evidence to support how the findings in the simulated environment translate to a valid representation of performance in the real clinical environment³. By doing so, authors help to convey the relevance and importance of their findings.

Limitations

Our consensus process has several limitations. Although we had a 75% response rate for our survey, an additional 20% of participants only partially completed the survey. This may have potentially introduced a selection bias, although the survey represented only one step in our consensus building process. We include a wide variety of experts in our consensus meeting, but many of them had a pediatric clinical background. We minimized this potential bias by ensuring that each breakout group had at least

one expert participant with a background outside of pediatrics. Furthermore, the principles of SBR are common across specialties and professions, and INSPIRE network members represent researchers who are recognized internationally for being leaders in SBR. We based our reporting guidelines on the CONSORT and STROBE guidelines developed by clinical researchers. Other guidelines could have been used as a starting point such as the American Education Research Association (AERA) standards developed in 2006⁵⁵. Our logic was to start with reporting guidelines that were applicable to all types of research, thus providing us more flexibility in generating extensions for both types of SBR. Cross-checking against the AERA guideline does not reveal areas we might have missed⁵⁶. While we tried to develop reporting guidelines for all types of SBR, we recognize there may be specific types of research that may require new items or different extensions. For example, studies designed to evaluate the validity of simulation-based assessments vary in their reporting requirements. The STAndards for Reporting of Diagnostic Accuracy (STARD) Statement⁵⁶ addresses these points, and a recent review operationalized these standards and applied them to SBR⁵⁷. Other reporting guidelines that might be amenable for simulation-specific extensions include the Consolidated criteria for reporting qualitative research (COREQ)⁵⁸, and the Standards for Quality Improvement Reporting Excellence (SQUIRE)⁵⁹ guidelines for reporting quality improvement studies. As the field of SBR grows, the simulation-specific extensions for the CONSORT and STROBE Statements may need to be revised or refined. We encourage authors, reviewers and editors to visit our website (<http://inspiresim.com/simreporting/>) and provide feedback that will be used to inform subsequent revisions to these reporting guidelines.

Conclusions

The unique features of SBR highlight the importance of clear and concise reporting that helps readers understand how simulation was used in the research. Poor and inconsistent reporting makes it difficult for readers to interpret results and replicate interventions, and hence less likely for research to inform change that will positively influence patient outcomes. The use of standardized reporting guidelines will serve as a guide for authors wishing to submit manuscripts for publication, and in doing so, draw attention to the important elements of SBR and ultimately improve the quality of simulation studies conducted in the future.

Acknowledgements

The principal investigator, Adam Cheng had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Adam Cheng, David Kessler, Ralph Mackinnon, Todd Chang, Vinay Nadkarni, Elizabeth Hunt, Jordan Duval-Arnould, David Cook, Martin Pusic, Joshua Hui, and Marc Auerbach participated in study design, the consensus building process, and drafting and revising the manuscript and approving the final version of the manuscript for publication. Yiqun Lin, David Moher and Matthias Egger contributed to interpretation of data, critically revising the manuscript for intellectual content, and approving the final version of the manuscript. All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy of the work are appropriately resolved.

Additional Contributors: The authors would like to thank and acknowledge the contributions of the following individuals who participated in the consensus building process by either completing the pre-meeting survey, attending the consensus meeting, or both: Dylan Bould, MBChB, MRCP, FRCA, Med, University of Ottawa; Ryan Brydges, PhD, University of Toronto; Michael Devita, MD, FCCM, FACP, Harlem Hospital Center; Jonathan Duff, MD, MEd, University of Alberta; Sandeep Gangadharan, MD, Hofstra University School of Medicine; Sharon Griswold-Theodorson, MD, MPH, Drexel University College of Medicine; Pam Jeffries, PhD, RN, FAAN, ANEF, George Washington University; Lindsay Johnston, MD, Yale University School of Medicine; Suzan Kardong-Edgren, PhD, RN, ANEF, CHSE, Robert Morris University; Arielle Levy, MD, MEd, University of Montreal; Lori Lioce, DNP, FNP-BC, CHSE, FAANP, The University of Alabama in Huntsville; Marco Luchetti, MD, MSc, A. Manzoni General Hospital; Tensing Maa, MD, Ohio State University College of Medicine; William McGaghie, PhD, Northwestern University Feinberg School of Medicine; Taylor Sawyer, DO, MEd, University of Washington School of Medicine; Dimitrios Stefanidis, MD, PhD, FACS, Carolinas HealthCare System; Kathleen Ventre, MD, Children's Hospital Colorado; Barbara Walsh, MD, University of Massachusetts School of Medicine; Mark Adler, MD, Feinberg School of Medicine, Northwestern University; Linda Brown, MD, MSCE, Alpert Medical School of Brown University; Aaron Calhoun, MD, University of Louisville; Aaron Donoghue, MD, MSCE, The Children's Hospital of Philadelphia; Tim Draycott, MD,

470 FRCOG, Southmead Hospital; Walter Eppich, MD, MEd, Feinberg School of Medicine, Northwestern
 471 University; Marcie Gawel, MSN, BSN, MS, Yale University; Stefan Gisin, MD, University Hospital Basel;
 472 Lou Halamek, MD, Stanford University; Rose Hatala, MD, MSc, University of British Columbia; Kim
 473 Leighton, PhD, RN, ANEF, DeVry Medical International's Institute for Research and Clinical Strategy;
 474 Debra Nestel, PhD, Monash University; Mary Patterson, MD, MEd, Cincinnati Children's Hospital;
 475 Jennifer Reid, MD, University of Washington School of Medicine; Elizabeth Sinz, MD, FCCM, Penn State
 476 University College of Medicine; G. Ulufer Sivrikaya, MD, Antalya Training and Research Hospital;
 477 Kimberly Stone, MD, MS, MA, University of Washington School of Medicine; Anne Marie Monachino,
 478 MSN, RN, CPN, Children's Hospital of Philadelphia; Michaela Kolbe, PhD, University Hospital Zurich;
 479 Vincent Grant, MD, FRCPC, University of Calgary; Jack Boulet, PhD, Foundation for Advancement of
 480 International Medical Education and Research; David Gaba, MD, Stanford University School of Medicine;
 481 Peter Dieckmann, PhD, Dipl-Psych, Danish Institute for Medical Simulation; Jeffrey Groom, PhD, CRNA,
 482 Florida International University; Chris Kennedy, MD, University of Missouri Kansas City School of
 483 Medicine; Ralf Krage, MD, DEAA, VU University Medical Center; Leah Mallory, MD, The Barbara Bush
 484 Children's Hospital at Maine Medical Center; Akira Nishisaki, MD, MSCE, The Children's Hospital of
 485 Philadelphia; Denis Oriot, MD, PhD, University Hospital of Poitiers; Christine Park, MD, Feinberg School
 486 of Medicine, Northwestern University; Marcus Rall, MD, InPASS Institute for Patient Safety and
 487 Teamtraining; Nick Sevdalis, PhD, King's College London; Nancy Tofil, MD, MEd, University of
 488 Alabama at Birmingham; Debra Weiner, MD, PhD, Boston Children's Hospital; John Zhong, MD,
 489 University of Texas Southwestern Medical Center; Donna Moro-Sutherland, MD, Baylor College of
 490 Medicine; Dalit Eyal, DO, St. Christopher's Hospital for Children; Sujatha Thyagarajan, DCH, FRCPCH,
 491 PediSTARS India; Barbara Ferdman, MD, University of Rochester Medical Center; Grace Arteaga, MD,
 492 FAAP, Mayo Clinic (Rochester); Tonya Thompson, MD, MA, The University of Arkansas for Medical
 493 Sciences; Kim Rutherford, MD, St. Christopher's Hospital for Children; Frank Overly, MD, Alpert
 494 Medical School of Brown University; Jim Gerard, MD, Saint Louis University School of Medicine;
 495 Takanari Ikeyama, MD, Aichi Children's Hospital and Medical Center; Angela Wratney, MD, MHSc,
 496 Children's National Medical Center; Travis Whitfill, MPH, Yale University School of Medicine; Nnenna
 497 Chime, MD, MPH, Albert Einstein College of Medicine; John Rice, PhD(c), US Department of the Navy

(retired); Tobias Everett, MBChB, FRCA, The Hospital for Sick Children; Wendy Van Ittersum, MD, Akron Children's Hospital; Daniel Scherzer, MD, Nationwide Children's Hospital; Elsa Vazquez Melendez, MD, FAAP, FACP, University of Illinois College of Medicine at Peoria; Chris Kennedy, MD, University of Missouri Kansas School of Medicine; Waseem Ostwani, MD, University of Michigan Health System; Zia Bismilla, MD, MEd, The Hospital for Sick Children; Pavan Zaveri, MD, MEd, Children's National Health System; Anthony Scalzo, MD, FACMT, FAAP, FAACT, Saint Louis University School of Medicine; Daniel Lemke, MD, Baylor College of Medicine; Cara Doughty, MD, MEd, Baylor College of Medicine; Modupe Awonuga, MD, MPH, MRCP(UK), FRCPC, FAAP, Michigan State University; Karambir Singh, MD, Johns Hopkins University School of Medicine; Melinda Fiedor-Hamilton, MD, MSc, Children's Hospital of Pittsburgh.

Financial Disclosure Summary

The authors would like to acknowledge the support of the Laerdal Foundation for Acute Medicine, who have previously provided infrastructure support for the INSPIRE network, and the Society for Simulation in Healthcare, who provided funding to cover the expenses of the consensus meeting.

Adam Cheng (study design, writing, editing and review of manuscript) is supported by: KidSIM-ASPIRE Simulation Infrastructure Grant, Alberta Children's Hospital Foundation, Alberta Children's Hospital Research Institute and the Department of Pediatrics, University of Calgary; Vinay Nadkarni (study design, writing, editing and review of manuscript) is supported by: Endowed Chair, Critical Care Medicine, Children's Hospital of Philadelphia; and the following research grants: AHRQ RO3HS021583; Nihon Kohden America Research Grant; NIH/NHLBI RO1HL114484; NIH U01 HL107681; NIH/NHLBI 1U01HL094345-01; and NIH/NINDS 5R01HL058669-10. David Moher (data interpretation, writing, editing and review of manuscript) is funded by a University Research Chair. Nick Sevdalis (collaborator) is funded by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care South London at King's College Hospital NHS Foundation Trust. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. Sevdalis delivers safety and team skills training on a consultancy basis to hospitals in the UK and

525 internationally via the London Safety & Training Solutions Ltd. The other authors have no other financial
526 or conflict of interests disclosures.

527

528

1. Cook DA, Hatala R, Brydges R et al. Technology enhanced simulation for health professions education: A systematic review and meta-analysis. *JAMA*. 2011; 3306:978-988.
2. Zendejas B, Brydges R, Wang AT, Cook DA. Patient outcomes in simulation-based medical education: a systematic review. *J Gen Intern Med*. 2013; 28:1078-1089.
3. Brydges R, Hatala R, Zendejas B, Erwin PJ, Cook DA. Linking Simulation-Based Educational Assessments and Patient-Related Outcomes: A Systematic Review and Meta-Analysis. *Acad Med*. 2015; 90:246-256.
4. Cheng A, Grant V, Auerbach M. Using simulation to improve patient safety: Dawn of a new era. *JAMA Pediatrics*. 2015; 169:419-420.
5. Cook DA. How much evidence does it take? A cumulative meta-analysis of outcomes of simulation-based education. *Med Educ*. 2014; 48:750-760.
6. McGaghie WC, Issenberg SB, Petrusa ER, Scalese RJ. A critical review of simulation-based medical education research: 2003–2009. *Med Educ*. 2010; 44:50–63
7. McGaghie WC, Issenberg SB, Cohen ER, Barsuk JH, Wayne DB. Translational educational research: a necessity for effective health-care improvement. *Chest* 2012; 142:1097-1103
8. Issenberg SB, McGaghie WC, Petrusa ER, Gordon DL, Scalese RJ. Features and uses of high-fidelity medical simulation that lead to effective learning: a BEME systematic review. *Medical Teacher*. 2005; 27:10-28.
9. Cheng A, Lockey A, Bhanji F, Lin Y, Hunt EA, Lang E. The Use of High-Fidelity Manikins for Advanced Life Support Training – A Systematic Review and Meta-analysis. *Resuscitation*, Published online April 14, 2015. DOI: <http://dx.doi.org/10.1016/j.resuscitation.2015.04.004>
10. Cheng A, Lang T, Starr S, Pusic M, Cook D. Technology-Enhanced Simulation and Pediatric Education: A Meta-analysis. *Pediatrics*. 2014; 133:e1313-1323.
11. Cheng A, Eppich W, Grant V, Sherbino J, Zendejas-Mummert B, Cook D. Debriefing for Technology-Enhanced Simulation: A Systematic Review and Meta-analysis. *Medical Education*. 2014; 48:657-666.
12. Ilgen JS, Sherbino J, Cook DA. Technology-enhanced simulation in emergency medicine: a systematic review and meta-analysis. *Academic Emergency Medicine*. 2013; 20:117-127.
13. Lorello GR, Cook DA, Johnson RL, Brydges R. Simulation-based training in anaesthesiology: a systematic review and meta-analysis. *Br J Anaesth*. 2014;112:231-245.
14. Zendejas B, Brydges R, Hamstra SJ, Cook DA. State of the evidence on simulation-based training for laparoscopic surgery: a systematic review. *Ann Surg*. 2013;257:586-593.
15. Dilaveri CA, Szostek JH, Wang AT, Cook DA. Simulation training for breast and pelvic physical examination: a systematic review and meta-analysis. *BJOG*. 2013;120:1171-1182.
16. Cheng A, Auerbach M, Chang T, Hunt EA, Pusic M, Nadkarni V, Kessler D. Designing and Conducting Simulation-based Research. *Pediatrics*. 2014; 133:1091-1101.
17. LeBlanc VR, Manser T, Weinger MB, Musson D, Kutzin J, Howard SK. The study of factors affecting human and systems performance in healthcare using simulation. *Simul Healthc*. 2011; 6:S24-S29.
18. Raemer D, Anderson M, Cheng A, Fanning R, Nadkarni V, Savoldelli G. Research regarding debriefing as part of the learning process. *Simul Healthc*. 2011; 6:S52-S57.
19. Cook DA, Hamstra SJ, Brydges R, et al. Comparative effectiveness of instructional design features in simulation-based education: systematic review and meta-analysis. *Med Teach*. 2013; 35:e867-898.
20. Glasziou P, Altman DG, Bossuyt P, et al. Reducing waste from incomplete or unusable reports of biomedical research. *Lancet*. 2014; 383: 267–76.
21. Cook DA, Beckman TJ, Bordage G. A systematic review of titles and abstracts of experimental studies in medical education: many informative elements missing. *Medical Education*. 2007; 41:1074-1081.
22. Cook DA, Beckman TJ, Bordage G. Quality of reporting of experimental studies in medical education: a systematic review. *Medical Education*. 2007; 41:737-745.
23. Cook DA, Levinson AJ, Garside S. Method and reporting quality in health professions education research: a systematic review. *Med Educ*. 2011;45:227-238.

24. Ju'ni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ*. 2001; 323:42-46.
25. Begg CB, Cho MK, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials: the CONSORT statement. *JAMA* 1996; 276: 637-639.
26. Begley CG, Ioannidis JP. Reproducibility in science: improving the standard for basic and preclinical research. *Circ Res*. 2015; 116:116-126.
27. Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. *Lancet*. 2001;357:1191-1194.
28. Moher D, Hopewell S, Schulz KF et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. *BMJ*. 2010; 340:c869.
29. Moher D, Altman DG, Schulz KF, Elbourne DR. Opportunities and challenges for improving the quality of reporting clinical research: CONSORT and beyond. *CMAJ*. 2004; 171:349-350.
30. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. *Med J Aust*. 2006;185:263-267.
31. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for Reporting Observational Studies. *Ann Intern Med*. 2007; 147:573-577.
32. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, et al., for the STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. *PLoS Med*. 2007; 4:e297
33. Moher D, Shamseer L, Clarke M et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews*. 2015; 4:1.
34. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Ann Intern Med*. 2009; 151:264-269.
35. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *Ann Intern Med*. 2009; 151:W65-94.
36. Enhancing the Quality and Transparency of Health Research. Equator Network library for health research reporting. <http://www.equator-network.org/library/>. Accessed May 28, 2015.
37. Golub RM, Fontanarosa PB. Researchers, readers and reporting guidelines: Writing between the lines. *JAMA*. 2015; 313:1625-1626.
38. Campbell MK, Elbourne DR, Altman DG; CONSORT group. CONSORT statement: extension to cluster randomised trials. *BMJ*. 2004; 328:702-708.
39. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. *JAMA*. 2006; 295:1152-1160
40. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Methods and Processes of the CONSORT Group: Example of an Extension for Trials Assessing Nonpharmacologic Treatments. *Ann Intern Med*. 2008; 148:W60-W66.
41. Little J, Higgins JP, Ioannidis JP et al. Strengthening the reporting of genetic association studies (STREGA) - an extension of the STROBE statement. *Eur J Clin Invest*. 2009; 39:247-266.
42. Moher D, Schulz KF, Simera I, Altman DG. Guidance for Developers of Health Research Reporting Guidelines. *PLoS Med*. 2010. 7(2):e1000217. doi:10.1371/journal.pmed.1000217
43. Cheng A, Hunt EA, Donoghue A, et al. Examining Pediatric Resuscitation Education Using Simulation and Scripting (EXPRESS): A Multicenter, Randomized-Controlled Trial. *JAMA Pediatrics*. 2013. 167:528-36.
44. Cheng A, Brown L, Duff J, et al. Improving CardioPulmonary Resuscitation with a CPR Feedback Device and Refresher Simulations (CPR CARES Study): A Multicenter, Randomized Trial. *JAMA Pediatrics*. 2015; 169(2):137-144.
45. Cheng A, Overly F, Kessler D, et al. Perception of CPR Quality: Influence of CPR Feedback, Just-in-Time Training and Provider Role. *Resuscitation*. 2015; 87: 44-50.
46. Kessler DO, Arteaga G, Ching K et al. Interns' success with clinical procedures in infants after simulation training. *Pediatrics*. 2013; 131:e811-20.
47. Gerard JM, Kessler DO, Braun C, Mehta R, Scalzo AJ, Auerbach M. Validation of global rating scale and checklist instruments for the infant lumbar puncture procedure. *Simul Healthc*. 2013;

- 8:148-154.
48. Kessler D, Pusic M, Chang TP et al. Impact of Just-in-Time and Just-in-Place simulation on intern success with infant lumbar puncture. *Pediatrics*. 2015; 135:e1237-1246.
 49. Chang TP, Kessler D, McAninch B et al. Script concordance testing: assessing residents' clinical decision-making skills for infant lumbar puncture. *Acad Med*. 2014; 89:128-135.
 50. Haubner LY, Barry JS, Johnston LC et al. Neonatal intubation performance: room for improvement in tertiary neonatal intensive care units. *Resuscitation*. 2013; 84:1359-1364.
 51. Common guidelines for education research and development. A Report from the Institute for Education Sciences, US Department of Education and the National Science Foundation. http://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf13126. Accessed January 10, 2015.
 52. Egger M, Schneider M, Davey Smith G. Spurious precision? Meta-analysis of observational studies. *BMJ*. 1998; 316:140-4.
 53. Cobo E, Cortes J, Ribera JM et al. Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial. *BMJ*. 2011; 343:d6783.
 54. Cook DA, Hamstra SJ, Brydges R, Zendejas B, Szostek JH, Wang AT, Erwin PJ, Hatala R. Comparative effectiveness of instructional design features in simulation-based education: systematic review and meta-analysis. *Med Teach*. 2013;35:e867-898.
 55. American Education Research Association. Standards for reporting on empirical social science research in AERA publications. *Educational Researcher*. 2006; 35:33-40.
 56. Bossuyt PM, Reitsma JB, Bruns DE et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. *BMJ*. 2003; 326:41-44.
 57. Cook DA, Brydges R, Zendejas B, Hamstra SJ, Hatala R. Technology-enhanced simulation to assess health professionals: a systematic review of validity evidence, research methods, and reporting quality. *Acad Med*. 2013; 88:872-883.
 58. Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. *Int J Qual Health Care*. 2007; 19(6):349-357.
 59. Davidoff F, Batalden P, Stevens D, Ogrinc G, Mooney S. Publication guidelines for quality improvement in health care: evolution of the SQUIRE project. *Ann Intern Med*. 2008; 149(9):670-676.

Table 1: Simulation-based Research Extensions for the CONSORT Statement

Item	Item no	CONSORT Description (Randomized, controlled trials)	Extension for Simulation-based Research
Title and abstract	1a, 1b	1a: Identification as a randomized trial in the title 1b: Structured summary of trial design, methods, results, and conclusions	In abstract or key terms the MESH or searchable keyword term must have the word “simulation” or “simulated”.
Introduction			
Background	2a, 2b	2a: Scientific background and explanation of rationale 2b: Specific objectives or hypotheses	Clarify whether simulation is <i>subject of research</i> or <i>investigational method for research</i> .
Methods			
Trial Design	3a, 3b	3a: Description of trial design (such as parallel, factorial) including allocation ratio 3b: Important changes to methods after trial commencement (such as eligibility criteria), with reasons	
Participants	4a, 4b	4a: Eligibility criteria for participants 4b: Settings and locations where the data were collected	
Interventions	5	The interventions for each group with sufficient details to allow for replication, including how and when they were actually administered	Describe the theoretical and/or conceptual rationale for the design of each intervention. Clearly describe all simulation-specific exposures, potential confounders, and effect modifiers.
Outcomes	6a, 6b	6a: Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed 6b: Any changes to trial outcomes after the trial commenced, with reasons	In describing the details of methods of assessment, include (when applicable) the setting, instrument, simulator type, timing in relation to the intervention, along with any methods used to enhance the quality of measurements. Provide evidence to support the validity and reliability of assessment tools in this context (if available).
Sample size / Study size	7a, 7b	7a: How sample size was determined 7b: When applicable, explanation of any interim analyses and stopping guidelines	
Randomization: Sequence generation	8a, 8b	8a: Method used to generate the random allocation sequence 8b: Type of randomization; details of any restriction (such as blocking and block size)	
Randomization: Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence	

		until interventions were assigned	
Randomization: Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	
Blinding (masking)	11a, 11b	11a: If done, who was blinded after assignments to interventions (for example, participants, care providers, those assessing outcomes) and how 11b: If relevant, description of the similarity of interventions	Describe strategies to decrease risk of bias, when blinding is not possible.
Statistical Methods	12a, 12b	12a: Statistical methods used to compare groups for primary and secondary outcomes 12b: Methods for additional analyses, such as subgroup analyses and adjusted analyses	Clearly indicate the unit of analysis (e.g. individual, team, system) and identify repeated measures on subjects, and describe how these issues were addressed.
Results			
Participant flow (a diagram is strongly recommended)	13a, 13b	13a: For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome 13b: For each group, losses and exclusions after randomization, together with reasons	
Recruitment	14a, 14b	14a: Dates defining the periods of recruitment and follow-up 14b: Why the trial ended or was stopped	
Baseline data	15	A table showing baseline demographic and clinical characteristics of each group	In describing characteristics of study participants, include their prior experience with simulation and other relevant features as related to the intervention(s).
Numbers analyzed	16	For each group, number of participants (denominator) included in each analysis and whether analysis was by original assigned groups	
Outcomes and estimation	17a, 17b	17a: For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) 17b: For binary outcomes, presentation of both absolute and relative effect sizes is recommended	For assessments involving more than one rater, inter-rater reliability should be reported.
Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	

Adverse Events	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	
Discussion			
Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	Specifically discuss the limitations of simulation-based research.
Generalizability	21	Generalizability (external validity) of the trial findings	Describe generalizability of simulation-based outcomes to patient-based outcomes (if applicable).
Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	
Other Information			
Registration	23	Registration number and name of trial registry	
Protocol	24	Where the full trial protocol can be accessed, if available	
Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	List simulator brand and if conflict of interest for intellectual property exists.

674
675
676

Table 2: Simulation-based Research Extensions for the STROBE Statement

Item	Item No	STROBE Description (Observational studies)	Extension for Simulation-based Research
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract. (b) Provide in the abstract an informative and balanced summary of what was done and what was found.	In abstract or key terms the MESH or searchable keyword term must have the word "simulation" or "simulated".
Introduction			
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported.	Clarify whether simulation is <i>subject of research</i> or <i>investigational method for research</i> .
Objectives	3	State specific objectives, including any pre-specified hypotheses.	
Methods			
Study Design	4	Present key elements of study design early in the paper.	
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection.	
Participants	6	(a) Cohort study: Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up. Case-control study: Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls. Cross-sectional study: Give the eligibility criteria, and the sources and methods of selection of participants. (b) Cohort study: For matched studies, give matching criteria and number of exposed and unexposed. Case-control study: For matched studies, give matching criteria and the number of controls per case.	
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and	Describe the theoretical and/or conceptual rationale for the design of the intervention / exposure.

		effect modifiers. Give diagnostic criteria, if applicable.	Describe the intervention / exposure with sufficient detail to permit replication. Clearly describe all simulation-specific exposures, potential confounders, and effect modifiers.
Data sources / measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group.	In describing the details of methods of assessment, include (when applicable) the setting, instrument, simulator type, timing in relation to the intervention, along with any methods used to enhance the quality of measurements. Provide evidence to support the validity and reliability of assessment tools in this context (if available).
Bias	9	Describe any efforts to address potential sources of bias.	
Study size	10	Explain how the study size was arrived at.	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why.	
Statistical Methods	12	(a) Describe all statistical methods, including those used to control for confounding. (b) Describe any methods used to examine subgroups and interactions. (c) Explain how missing data were addressed. (d) Cohort study: If applicable, explain how loss to follow-up was addressed. Case-control study: If applicable, explain how matching of cases and controls was addressed. Cross-sectional study: If applicable, describe analytical methods taking account of sampling strategy. (e) Describe any sensitivity analyses.	Clearly indicate the unit of analysis (e.g. individual, team, system) and identify repeated measures on subjects, and describe how these issues were addressed.
Results			
Participants	13	(a) Report the numbers of individuals at each stage of the study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analyzed.	

		(b) Give reasons for nonparticipation at each stage. (c) Consider use of a flow diagram.	
Descriptive data	14	(a) Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders. (b) Indicate the number of participants with missing data for each variable of interest. (c) Cohort study: Summarize follow-up time—e.g., average and total amount.	In describing characteristics of study participants, include their prior experience with simulation and other relevant features as related to the intervention(s).
Outcome data	15	Cohort study: Report numbers of outcome events or summary measures over time. Case-control study: Report numbers in each exposure category or summary measures of exposure. Cross-sectional study: Report numbers of outcome events or summary measures.	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence intervals). Make clear which confounders were adjusted for and why they were included. (b) Report category boundaries when continuous variables were categorized. (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period.	d) For assessments involving more than one rater, inter-rater reliability should be reported.
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions and sensitivity analyses.	
Discussion			
Key results	18	Summarize key results with reference to study objectives.	
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	Specifically discuss the limitations of simulation-based research.
Interpretation	20	Give a cautious overall interpretation of results	

		considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	
Generalizability	21	Discuss the generalizability (external validity) of the study results.	Describe generalizability of simulation-based outcomes to patient-based outcomes (if applicable).
Other Information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based.	List simulator brand and if conflict of interest for intellectual property exists.

679
680
681

682 Table 3: Key Elements to Report for Simulation-based Research
683

Elements*	Sub-elements**	Descriptor
Participant Orientation	Orientation to the simulator	Describe how participants were oriented to the simulator (eg. method, content, duration).
	Orientation to the environment	Describe how participants were oriented to the environment (eg. method, content, duration).
Simulator Type ¹⁶	Simulator make and model	Describe the simulator make and model.
	Simulator functionality	Describe functionality and/or technical specifications that are relevant to the research question. Describe modifications, if any. Describe limitations of the simulator.
Simulation Environment ¹⁶	Location	Describe where the simulation was conducted (eg. in situ clinical environment, simulation center etc)
	Equipment	Describe the nature of the equipment available (eg. type, amount, location, size etc)
	External stimuli	Describe any external stimuli (eg. background noise)
Simulation Event / Scenario ¹⁶	Event description	Describe if the event was programmed and/or scripted (eg. orientation to event, scenario progression, triggers). If a scenario was utilized, the scenario script should be provided as an appendix.
	Learning objectives	List the learning objectives and describe how they were incorporated into the event
	Group vs individual practice	Describe if the simulation was conducted in groups or as individuals.
	Use of adjuncts	Describe if adjuncts (eg. moulage, media, props) were used.
	Facilitator / operator characteristics	Describe experience (eg. clinical, educational), training (eg. fellowship, courses), profession.
	Pilot testing	Describe if pilot testing was conducted (eg. number, duration, frequency).
	Actors / Confederates / Standardized/Simulated Patients ¹⁶	Describe experience (eg. clinical, educational), training (eg. fellowship, courses), profession, gender. Describe various roles, including training, scripting, orientation, and compliance with roles.
Instructional Design (for educational interventions) ⁵³ or Exposure (for	Duration	Describe the duration of the educational intervention. If the intervention involves more than one segment, describe the duration of each segment.

simulation as investigative methodology) ¹⁶	Timing	Describe the timing of the educational intervention relative to the time when assessment / data collection occurs (eg. just-in-time training).
	Frequency / Repetitions	Describe how many repetitions were permitted and/or the frequency of training (eg. deliberate practice).
	Clinical Variation	Describe the variation in clinical context (eg. multiple different patient scenarios).
	Standards / Assessment	Describe pre-defined standards for participant performance (eg. mastery learning) and how these standards were established.
	Adaptability of Intervention	Describe how the training was responsive to individual learner needs (eg. individualized learning)
	Range of Difficulty	Describe the variation in difficulty or complexity of the task
	Non-simulation interventions and adjuncts	Describe all other non-simulation interventions (eg. lecture, small group discussion) or educational adjuncts (eg. educational video), how they were used, and when they were used relative to the simulation intervention.
	Integration	Describe how the intervention was integrated into curriculum
Feedback and/or Debriefing ¹¹	Source	Describe the source of feedback (eg. computer, simulator, facilitator).
	Duration	Describe the amount of time spent.
	Facilitator Presence	Describe if a facilitator was present (yes / no), and if so, how many facilitators.
	Facilitator Characteristics	Describe experience (eg. clinical, educational), training (eg. fellowship, courses), profession, gender.
	Content	Describe content (eg. teamwork, clinical, technical skills and/or inclusion of quantitative data etc).
	Structure / Method	Describe the method of debriefing / feedback and debriefing framework utilized (ie. phases).
	Timing	Describe when the feedback and/or debriefing was conducted relative to the simulation event (eg. terminal vs. concurrent).
	Video	Describe if video was used (yes / no), and how it was used.

	Scripting	Describe if a script was used (yes / no) and provide script details as an appendix.
--	-----------	-------------------------------------------------------------------------------------

* These elements may apply for the simulation intervention (eg. RCT or observational study with simulation as an educational intervention) or when simulation is the environment for research (eg. RCT or observational study utilizing simulation as an investigative methodology). Elements should be described in sufficient detail to permit replication.

**Description required only if applicable